Intracavernous injections of prostaglandin E1 for erectile dysfunction: Patient satisfaction and quality of sex life on long-term treatment

Journal of Sexual Medicine

Volumn 4, Issue 2, 2007, Pages 426-431

  Alexandre, Benjamin ^a   Lemaire, Antoine ^a   Desvaux, Pierre ^b   Amar, Edouard ^c  

^a Association pour le Developpement de l'Information et de la Recherche sur la SexualiteADIRS   (France)

^b Hôpital Cochin ^*  (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Erectile dysfunction; Intracavernous injection; Patient satisfaction; Prostaglandin E1

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; EXPECTATION; HUMAN; INJECTION SITE PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PATIENT SATISFACTION; PENIS ERECTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF ESTEEM; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; TREATMENT DURATION;

EID: 33947131712     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2006.00260.x     Document Type: Article

References (13)

1. Urciuoli R, Cantisani TA, Carlini IM, Giuglietti M, Botti FM. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev 2004; (2): CD001784.
2. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334: 873-7.
3. Porst H, Buvat J, Meuleman E, Michal V, Wagner G. Intracavernous alprostadil alfadex - An effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res 1998; 10: 225-31.
4. Porst H. The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience. J Urol 1996; 155: 802-15.
5. Hatzichristou DG, Apostololidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A. Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol 2000; 164: 1197-200.
6. Kunelius P, Lukkarinen O. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction. Int J Impot Res 1999; 11: 21-4.
7. Gheorghiu S, Godschalk M, Gentili A, Mulligan T. Quality of life in patients using self-administered intracavernous injections of prostaglandin E1 for erectile dysfunction. J Urol 1996; 156: 80-1.
8. Willke RJ, Yen W, Parkerson GR Jr, Erder MH, Glick HA. Quality of life effects of alprostadil therapy for erectile dysfunction: Results of a trial in Europe and South Africa. Int J Impot Res 1998; 10: 239-46.
9. Choi HK, Adimoelja A, Kim SC, Soebadi DM, Seong DH, Garceau RJ. A dose-response study of alprostadil sterile powder (S.Po.) (Caverject) for the treatment of erectile dysfunction in Korean and Indonesian men. Int J Impot Res 1997; 9: 47-51.
10. Weiss JN, Badlani GH, Ravalli R, Brettschneider N. Reasons for high drop-out rate with self-injection therapy for impotence. Int J Impot Res 1994; 6: 171-4.
11. Shabsigh R, Padma-Nathan H, Gittleman M, McMurray J, Kaufman J, Goldstein I. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: A comparative, randomized, crossover, multicenter study. Urology 2000; 55: 109-13.
12. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, Saenz de Tejada I, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004; 1: 6-23.
13. Lane BZ, Ausmundson SJ, Butler RS, Zippe CD, Jones JS, Lakin MM. Use of a Visual Analog Scale to assess pain of injection with intracavernous injection therapy. J Sex Med 2005; 2: 428-31.